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Objectives. Consistent evidence suggests an inverse and independent association between handgrip 
strength and arterial thrombotic disease. However, whether handgrip strength is related to future risk of 
venous thromboembolism (VTE) is uncertain. We sought to assess the prospective association between 
handgrip strength and VTE risk. Design. Handgrip strength was assessed using a hand dynamometer in a 
population-based sample of 864 men and women aged 61-74 years without a history of VTE at baseline 
in the Kuopio Ischemic Heart Disease prospective cohort study. Handgrip strength was allometrically 
scaled to account for the effect of body weight (handgrip strength/body weight2/3) and to normalize the 
data. Hazard ratios (HRs) with 95% confidence intervals (CIs) were estimated for VTE. Results. During a 
median (interquartile range) follow-up of 17.2 (12.1-18.3) years, 58 VTE events were recorded. The risk 
of VTE did not significantly decrease per 1 standard deviation increase in normalized handgrip strength in 
age- and sex-adjusted analysis (HR 0.89; 95% CI 0.65–1.22). The association remained similar in 
analyses adjusted for several established and emerging risk factors (HR 0.90; 95% CI 0.65–1.25). The 
corresponding adjusted HRs were 1.10 (95% CI: 0.56-2.18) and 1.15 (95% CI: 0.57-2.34) respectively, 
when comparing the extreme tertiles of normalized handgrip strength values. Conclusions. Normalized 
handgrip strength is not associated with future VTE risk in an older Caucasian population. Large-scale 
studies in other populations and age-groups are warranted to generalize these findings.  
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The role of physical activity in the prevention of atherosclerotic vascular disease and mortality is well 
established [1]. Physical activity has also been recently shown to be associated with reduced risk of 
venous thromboembolism (VTE) [2].  Venous thromboembolism which comprises of deep vein 
thrombosis (DVT) and pulmonary embolism (PE), constitutes a significant public health burden, given its 
substantial morbidity, premature mortality, as well as high costs to health systems [3,4].  Venous 
thromboembolism and atherosclerotic cardiovascular disease (CVD) are closely related disease conditions 
and they seem to share common risk factors such as obesity and cigarette smoking [5-7]. Evidence 
suggests they share common pathophysiological mechanisms such as coagulation, platelet activation and 
dyslipidaemia [8]. Physical fitness is a strong predictor of future health status[9] with its main 
components being cardiorespiratory fitness (CRF) and muscular fitness [10]. The inverse and independent 
relationship between CRF and vascular diseases is well established [9]. Limited but emerging evidence 
suggests CRF may also be linked to VTE risk [11-14]. The main components of muscular fitness include 
muscular strength, muscular endurance and muscular power [10]. Among these, muscular strength has 
been the most widely studied in terms of its relationship to health outcomes. Handgrip strength has 
commonly been used as a typical measure of muscular strength. The emerging evidence on the inverse 
and independent relationship between handgrip strength and atherosclerotic CVD is consistent [15,16]. 
Given the overall evidence and inter-relationship between physical fitness, atherosclerotic CVD, and 
VTE, we hypothesized that handgrip strength may be linked to the risk of VTE. A previous evaluation of 
the association between handgrip strength and VTE risk in individuals aged 70 years and older by 
Engbers and colleagues demonstrated that low handgrip strength (<15th percentile) was associated with a 
2.3 times higher risk of VTE compared to high handgrip strength ((>15th percentile) [17]; however, this 







In this context, we sought to assess the prospective association between handgrip strength and VTE risk 
in a general population-based cohort of Finnish men and women. We accounted for the effect of body 
weight on handgrip strength using allometric scaling to normalize the data. 
 
Methods 
Study design and population 
This study was reported in accordance with the STROBE (STrengthening the Reporting of OBservational 
studies in Epidemiology) guidelines for reporting observational studies in epidemiology (Supplementary 
Material 1).[18] Participants in the current analyses were part of the Kuopio Ischemic Heart Disease 
(KIHD) risk factor study, a prospective population-based cohort study designed to investigate risk factors 
for vascular disease and other chronic disease outcomes. The study recruitment methods, blood sample 
collection procedures and examinations have been described previously [19]. The initial cohort comprised 
a representative sample of men randomly recruited from the city of Kuopio and surrounding rural 
communities in eastern Finland using a population register. These participants underwent re-examinations 
at 4 years, 11 years and 20 years after study entry. In the 11-year follow-up re-examinations, women were 
invited to join the study and they formed part of the cohort employed for this analysis. A total of 2,358 
participants (1,007 men and 1,351 women) aged 53 to 74 years at baseline were initially recruited [19]. Of 
the 2,072 participants found to be potentially eligible, 193 did not agree to participate, 66 did not respond 
to the invitation and 39 declined to provide informed consent, which left 1,774 participants 
(Supplementary Material 2) [19]. The current analysis is based on 864 men and women with complete 
information on handgrip strength, relevant covariates, and VTE events, who had baseline examinations 
conducted from March 1998 to December 2001. The research protocol was approved by institutional 







number 143/97). Written informed consent was obtained from all participants and all study procedures 
were conducted according to the Declaration of Helsinki.  
 
Assessment of handgrip strength, risk markers and outcome 
Handgrip strength of the dominant hand for each participant was measured by a hand dynamometer (in 
kPa; Martin-Balloon-Vigorimeter; Gebrüder Martin, Tuttlingen, Germany). The MartinVigorimeter is 
known for its high reliability and accuracy, especially in older patients [20]. Two measurements were 
taken and the mean of both values was used for analysis. The dynamometers were calibrated at the 
beginning of each test and there was a one-minute resting gap between both handgrip measurements. 
Absolute values of handgrip strength were allometrically scaled to account for the influence of body 
weight and to normalize the data (normalized handgrip strength = handgrip strength/body weight2/3) [21]. 
All results were multiplied by 100 for easier readability. 
All first lifetime VTE events that occurred from study enrollment through to 2017 were included. 
The diagnosis of DVT or PE required positive imaging tests and they were identified by computer linkage 
to the National Hospital Discharge Registry data maintained by the Finnish Institute for Health and 
Welfare. The medical documents for each potential VTE case were cross-checked in detail and VTE 
events were validated by two physicians who were blinded to the exposures. The ICD 10 codes (I26, I80 
and I82) were used to code and classify each potential VTE case. 
 
Statistical analysis 
Using descriptive analyses, baseline characteristics were presented as means (standard deviation, SD) or 
medians (interquartile range, IQR) for continuous variables and percentages for categorical variables. 







models after confirming no substantial departure from the assumptions of proportionality of hazards [22]. 
Normalized handgrip strength was modeled as both continuous [per SD increase] and categorical (tertiles) 
exposures. In a subsidiary analysis, normalized handgrip strength was also modelled as percentiles (≥ 15th 
percentile versus < 15th percentile) to maintain consistency with a previous study [17]. Hazard ratios were 
adjusted for in three models: (1) unadjusted; (2) age and sex; and (3) plus body height, smoking status, 
prevalent coronary heart disease (CHD), history of diabetes mellitus, use of lipid medication, physical 
activity, and prevalent cancer. All statistical analyses were conducted using Stata version MP 16 (Stata 
Corp, College Station, Texas). 
 
Results 
The overall mean (SD) age of study participants at study entry was 69 (3) years and 47.2% were males. 
The mean (SD) values of normalized handgrip strength and weight were 0.48 (0.22) kPa/kg2/3 and 75.5 
(12.9) kg respectively (Table 1). During a median (IQR) follow-up of 17.2 (12.1-18.3) years, a total of 58 
VTE cases (annual rate 4.54/1,000 person-years at risk; 95% CI: 3.51 to 5.87) occurred. The high VTE 
event rate potentially reflects the older age, high body mass and high prevalence of CHD in the study 
sample (Table 1); these are all established risk factors for VTE [23]. The HR for VTE per 1 SD increase 
in normalized handgrip strength in unadjusted analysis was 0.91 (95% CI: 0.67 to 1.22), which remained 
similar when adjusted for age and sex 0.89 (95% CI: 0.65 to 1.22) and further adjustment for established 
risk factors and other potential confounders (body height, smoking status, prevalent CHD, history of type 
2 diabetes, use of lipid medication, physical activity, and prevalent cancer) 0.90 (95% CI: 0.65 to 1.25) 
(Table 2). The corresponding adjusted HRs were 1.13 (95% CI: 0.58 to 2.17), 1.10 (95% CI: 0.56 to 
2.18), and 1.15 (95% CI: 0.57 to 2.34) respectively, when comparing the top versus bottom tertiles of 







comparing participants above the 15th percentile normalized handgrip strength with those below below 
(Supplementary material 3). 
 
Discussion 
Summary of main findings 
Previous prospective observational data on the inverse and independent association between handgrip 
strength (a measure of muscular strength) and arterial thrombotic disease is plentiful [15,16]. Muscular 
strength has also been demonstrated to be inversely associated with cardiometabolic conditions such as 
type 2 diabetes and metabolic syndrome [24,25]. In this first study to evaluate the prospective association 
between normalized handgrip strength and risk of VTE in a general population-based cohort of older 
Caucasian men and women, we found no evidence of an association. These findings may seem 
unexpected given that a previous study based on a case-control design showed that weak handgrip 
strength was associated with an increased risk of VTE in individuals aged 70 years and older [17]. 
However, because of the lack of temporality in the study design, the findings were prone to reverse 
causation bias. Furthermore, our findings were unexpected given the close inter-relationship between 
atherosclerotic CVD, VTE and physical fitness and also the fact that handgrip strength is a measure of 
whole-body muscle strength, correlated with leg strength, provides a valid index of overall limb muscle 
strength, and characterizes physical capability [26].  
 
Possible explanations for findings 
Pathways postulated to underlie the protective effect of higher muscular strength (handgrip strength) on 
vascular disease have included reduction in incidence of weight gain, abdominal adiposity, insulin 







observed in our study may reflect important pathophysiologic differences between arterial thrombotic 
disease and VTE. There is still uncertainty as to whether arterial thrombotic disease (comprising of CHD, 
stroke, and peripheral artery disease) is related to VTE. It has been suggested that atherosclerotic CVD is 
an underlying condition and precedes the development of VTE [28]; however, evidence on the contrary 
also suggests this is not the case [29,30]. There is controversy as to whether any relationship between 
atherosclerotic CVD and VTE may reflect shared risk factors. Whereas some studies have demonstrated 
significant associations between traditional CVD risk factors and VTE risk [5,7], others have not [6,31]. 
Atherosclerotic CVD and VTE have historically been viewed as two distinct diseases [32] and based on 
findings that traditional risk factors for VTE and arterial thrombotic disease are not similar, it is generally 
believed that their pathogenesis differ [33]. On the contrary, the absence of evidence of an association 
could also be related to study design factors and population characteristics such as (i) low statistical 
power due to the low number of VTE events; (ii) regression dilution bias due to the long follow-up 
duration; (iii) residual confounding; and (iv) age, sex, or genetic background of the population. Given the 
absence of previous prospective evaluations of the associations, large-scale studies are warranted to 
confirm or refute these findings. 
 
Strengths and limitations 
The notable strengths of this study include the novelty (prospective cohort design), the general 
population-based sample of men and women with no history of pre-existing VTE at study entry, 
employment  of the Martin Vigorimeter for measuring grip strength, long and complete follow-up of 
participants, and reliable data on a comprehensive panel of lifestyle factors which allowed adjustment for 
potential confounding. Limitations which merit mention include  (i) the relatively low number of VTE 







confounding due to unmeasured confounding; (iii) inability to generalise the findings to other 
populations; (iv) inability to correct for regression dilution bias due to absence of repeat measurements of 
handgrip strength; and (v) data was available on only total VTEs which precluded the ability to evaluate 
specific VTE outcomes (DVT or PE). 
 
Conclusions 
Normalized handgrip strength is not associated with future VTE risk in an older Caucasian population. 
Large-scale studies in other populations and age-groups are warranted to generalize these findings.  
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Table 1. Baseline participant characteristics 
 










Mean (SD), median 
(IQR), or n (%) 
 
Mean (SD), median 
(IQR), or n (%)  
 
Mean (SD), median 
(IQR), or n (%) 
 
Mean (SD), median 
(IQR), or n (%) 
Normalized handgrip strength 
(kPa/kg2/3) 
0.48 (0.22) 0.30 (0.06) 0.45 (0.04) 0.70 (0.25) 
     
Questionnaire/Prevalent conditions     
Age at survey (years) 69 (3) 69 (3) 69 (3) 68 (3) 
Males 408 (47.2) 176 (61.1) 153 (53.1) 79 (27.4) 
History of type 2 diabetes 83 (9.6) 32 (11.1) 28 (9.7) 23 (8.0) 
Current smokers 81 (9.4) 23 (8.0) 27 (9.4) 31 (10.8) 
History of CHD 308 (35.7) 126 (43.8) 103 (35.8) 79 (27.4) 
History of cancer 89 (10.3) 26 (9.0) 30 (10.4) 33 (11.5) 
Use of cholesterol medication 54 (6.3) 23 (8.0) 16 (5.6) 15 (5.2) 
     
Physical measurements     
Weight (kg) 75.5 (12.9) 86.5 (10.8) 76.5 (7.5) 63.3 (2.9) 
Height (cm) 164.2 (9.0) 167.3 (9.1) 165.1 (8.3) 160.3 (8.1) 
BMI (kg/m2) 28.0 (4.3) 31.0 (4.1) 28.2 (3.2) 24.7 (2.9) 
SBP (mmHg) 138 (18) 138 (18) 140 (17) 137 (18) 
DBP (mmHg) 80 (9) 81 (18) 80 (8) 78 (9) 
Energy expenditure of total LTPA 
(kcal/day) 
378 (226-649) 387 (246-614) 411 (239-703) 343 (197-584) 
     
Blood-based markers     
Total cholesterol (mmol/l) 5.44 (0.94) 5.34 (0.89) 5.46 (1.00) 5.54 (0.93) 
HDL-C (mmol/l) 1.24 (0.32) 1.15 (0.28) 1.22 (0.31) 1.35 (0.33) 
 
BMI, body mass index; CHD, coronary heart disease; CI, confidence interval; DBP, diastolic blood pressure; HDL-C, high-density lipoprotein 













Model 1  Model 2  Model 3  
  HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value 
Per 1 SD increase 58 / 864 0.91 (0.67 to 1.22) 0.52 0.89 (0.65 to 1.22) 0.47 0.90 (0.65 to 1.25) 0.53 
T1 (0.12-0.38) 16 / 288 ref  ref  ref  
T2 (0.39-0.52) 22 / 288 1.32 (0.69 to 2.50) 0.40 1.31 (0.69 to 2.49) 0.42 1.36 (0.70 to 2.62) 0.36 
T3 (0.53-4.03) 20 / 288 1.13 (0.58 to 2.17) 0.72 1.10 (0.56 to 2.18) 0.78 1.15 (0.57 to 2.34) 0.70 
 
CI, confidence interval; HR, hazard ratio; ref, reference; SD, standard deviation; T, tertile 
Model 1: Unadjusted 
Model 2: Adjusted for age and sex 
Model 3: Model 2 plus body height, smoking status, prevalent coronary heart disease, history of type 2 diabetes, use of lipid 












STROBE 2007 Statement—Checklist of items that should be included in 
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Supplementary material 1: STROBE 2007 Statement—Checklist of items that should be included in 





Reported on page 
# 
 Title and abstract 1 (a) Indicate the study’s design with a commonly used term in the title 
or the abstract 
Page 1 
(b) Provide in the abstract an informative and balanced summary of 
what was done and what was found 
Page 2 
Introduction  
Background/rationale 2 Explain the scientific background and rationale for the investigation 
being reported 
Page 3 
Objectives 3 State specific objectives, including any prespecified hypotheses Page 3 
Methods  
Study design 4 Present key elements of study design early in the paper Study design and 
population 
 
Setting 5 Describe the setting, locations, and relevant dates, including periods of 
recruitment, exposure, follow-up, and data collection 
Study design and 
population 
 
Participants 6 (a) Give the eligibility criteria, and the sources and methods of selection 
of participants. Describe methods of follow-up 
Study design and 
population 
 
(b) For matched studies, give matching criteria and number of exposed 
and unexposed 
Study design and 
population 
 
Variables 7 Clearly define all outcomes, exposures, predictors, potential 
confounders, and effect modifiers. Give diagnostic criteria, if applicable 
Assessment of 
handgrip strength, 





8*  For each variable of interest, give sources of data and details of 
methods of assessment (measurement). Describe comparability of 
assessment methods if there is more than one group 
Assessment of 
handgrip strength, 
risk markers and 
outcome 
 
Bias 9 Describe any efforts to address potential sources of bias Statistical analysis 
 
Study size 10 Explain how the study size was arrived at Statistical analysis 
 
Quantitative variables 11 Explain how quantitative variables were handled in the analyses. If 
applicable, describe which groupings were chosen and why 
Statistical analysis 
 




(b) Describe any methods used to examine subgroups and interactions Statistical analysis 
 




(d) If applicable, explain how loss to follow-up was addressed Not applicable 




Participants 13* (a) Report numbers of individuals at each stage of study—eg numbers 
potentially eligible, examined for eligibility, confirmed eligible, included 
in the study, completing follow-up, and analysed 
Supplementary 
material 3 
  (b) Give reasons for non-participation at each stage Supplementary 
material 3 
  (c) Consider use of a flow diagram Supplementary 
material 3 
Descriptive data 14* (a) Give characteristics of study participants (eg demographic, clinical, 
social) and information on exposures and potential confounders 
Results; Table 1  
  (b) Indicate number of participants with missing data for each variable 
of interest 
 
  (c) Summarise follow-up time (eg, average and total amount) Results 
Outcome data 15* Report numbers of outcome events or summary measures over time Results 
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted 
estimates and their precision (eg, 95% confidence interval). Make clear 
which confounders were adjusted for and why they were included 
Results; Table 2 
  (b) Report category boundaries when continuous variables were 
categorized 
Results; Table 2 
  (c) If relevant, consider translating estimates of relative risk into 
absolute risk for a meaningful time period 
 
Other analyses 17 Report other analyses done—eg analyses of subgroups and 
interactions, and sensitivity analyses 
Not applicable 
Discussion 
   
Key results 18 Summarise key results with reference to study objectives Discussion - 
Summary of main 
findings 
Limitations    
Interpretation 20 Give a cautious overall interpretation of results considering objectives, 
limitations, multiplicity of analyses, results from similar studies, and 
other relevant evidence 
Discussion 
Generalisability 21 Discuss the generalisability (external validity) of the study results Discussion 
Other information 
   
Funding 22 Give the source of funding and the role of the funders for the present 
study and, if applicable, for the original study on which the present 






Supplementary material 2: Participant flow 
Remaining participants
n = 1774
(920 women and 854 men)
Data on handgrip strength, risk factors 
and outcomes were available for 864
participants 
(456 women and 408 men)
Baseline examination
Years 1998−2001
Invited, n = 2358
(1351 women and 1007 men)
- Death 72
- Severe illness 135
- Migrated 20
- Unknown address 5
Eligible, n = 2072
(1173 women and 899 men)
- Refused 193
- No contact 66 
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Model 1  Model 2  Model 3  
  HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value 
< 15th percentile 6 / 118 ref  ref  ref  
≥ 15th percentile 52 / 746 1.20 (0.51 to 2.79) 0.68 1.19 (0.51 to 2.80) 0.69 1.27 (0.53 to 3.04) 0.60 
 
CI, confidence interval; HR, hazard ratio; ref, reference 
Model 1: Unadjusted 
Model 2: Adjusted for age and sex 
Model 3: Model 2 plus body height, smoking status, prevalent coronary heart disease, history of type 2 diabetes, use of lipid 
medication, physical activity, and prevalent cancer 
 
 
 
 
 
 
 
 
 
 
 
